Flotillin-2: A new potential predictor for prognosis of breast cancer
Sascha Pust, first author
Overexpression of ErbB2 occurs in up to 30% of human breast cancers. ErbB2 is not down-regulated by ligand-induced mechanisms as many other receptors. In a new study now published in Oncogene (journal impact factor 6.4), Sascha Pust (photo) from Kirsten Sandvig's group at the Institute for Cancer Research and coworkers show that flotillins stabilize ErbB2 at the plasma membrane. Moreover, microarray analysis of biopsies of 194 breast cancer patients indicated that flotillin-2 is a good prognostic marker for breast cancer. Depletion of flotillins leads to internalization and degradation of ErbB2, thereby inhibiting the ErbB2-triggered signaling.
This study was a collaboration between several groups, including three groups (Sandvig, Danielsen, Liestøl) from the Center for Cancer Biomedicine (CCB).
From major journals, first or last author from the Institute for Cancer Research
Bergholtz H, Norum JH, Lien TG, Skrede ML, Garred Ø, Sørlie T(2025) B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses Breast Cancer Res, 27(1), 44 DOI 10.1186/s13058-025-01990-2, PubMed 40119362
Tanoli Z, Fernández-Torras A, Özcan UO, Kushnir A, Nader KM, Gadiya Y, Fiorenza L, Ianevski A, Vähä-Koskela M, Miihkinen M, Seemab U, Leinonen H, Seashore-Ludlow B, Tampere M, Kalman A, Ballante F, Benfenati E, Saunders G, Potdar S, Gómez García I, García-Serna R, Talarico C, Beccari AR, Schaal W, Polo Aet al.(2025) Computational drug repurposing: approaches, evaluation of in silico resources and case studies Nat Rev Drug Discov(in press) DOI 10.1038/s41573-025-01164-x, PubMed 40102635
Skotland T, Ekroos K, Llorente A, Sandvig K(2025) Quantitative Lipid Analysis of Extracellular Vesicle Preparations: A Perspective J Extracell Vesicles, 14(3), e70049 DOI 10.1002/jev2.70049, PubMed 40091364
Rea A, Santana-Hernández S, Villanueva J, Sanvicente-García M, Cabo M, Suarez-Olmos J, Quimis F, Qin M, Llorens E, Blasco-Benito S, Torralba-Raga L, Perez L, Bhattarai B, Alari-Pahissa E, Georgoudaki AM, Balaguer F, Juan M, Pardo J, Celià-Terrassa T, Rovira A, Möker N, Zhang C, Colonna M, Spanholtz J, Malmberg KJet al.(2025) Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression Nat Immunol(in press) DOI 10.1038/s41590-025-02103-z, PubMed 40119192
Bergholtz H, Norum JH, Lien TG, Skrede ML, Garred Ø, Sørlie T(2025) B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses Breast Cancer Res, 27(1), 44 DOI 10.1186/s13058-025-01990-2, PubMed 40119362
Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K(2025) Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study Acta Oncol, 64, 439-447 DOI 10.2340/1651-226X.2025.43045, PubMed 40105683